A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group study (PZ586)

William J. Tester, Kyung Mann Kim, Robert L. Krigel, Philip D. Bonomi, John H. Glick, Robert F. Asbury, John M. Kirkwood, Ronald H. Blum, Joan H. Schiller

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Interleukin-2 (IL-2) and beta-interferon (β-IFN) are biologic agents with antitumor activity observed in preclinical models. Some studies of patients with advanced non-small cell lung cancer treated with IL-2 report relatively long survival, despite low response rates. Seventy-six evaluable patients with stage IV non-small cell lung cancer were treated in a randomized Phase II study with either IL-2 alone or IL-2 plus β-IFN. Patients received either IL-2 at 6x106 Cetus units/m2 3 days weekly or the combination of IL-2 at 5x106 Cetus units/m2 plus β-IFN at 6x106 units/m2, both given 3 days weekly. Both biologic agents were administered by intravenous bolus injection on an outpatient basis. Objective responses were observed in 3/76 (4%) patients. Grade 4 toxicity occurred in 3/39 patients treated with IL-2 alone, and in 4/37 patients treated with IL-2 plus β-IFN. An additional lethal respiratory toxicity occurred in a patient who received IL-2 plus β-IFN. The median survival of all patients treated on this study was 33 weeks. Despite producing only a 4% objective response rate, IL-2 appears to have a favorable impact on survival comparable to chemotherapy. The role for this immune therapy in the management of non-small cell lung cancer requires further study. Copyright (C) 1999 Elsevier Science Ireland Ltd.

Original languageEnglish (US)
Pages (from-to)199-206
Number of pages8
JournalLung Cancer
Volume25
Issue number3
DOIs
StatePublished - Sep 1999

Fingerprint

Interferon-beta
Non-Small Cell Lung Carcinoma
Interleukin-2
Biological Factors
Survival
Intravenous Injections
Outpatients
Drug Therapy

Keywords

  • Beta-interferon
  • Interleukin-2
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Oncology

Cite this

A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group study (PZ586). / Tester, William J.; Kim, Kyung Mann; Krigel, Robert L.; Bonomi, Philip D.; Glick, John H.; Asbury, Robert F.; Kirkwood, John M.; Blum, Ronald H.; Schiller, Joan H.

In: Lung Cancer, Vol. 25, No. 3, 09.1999, p. 199-206.

Research output: Contribution to journalArticle

Tester, William J. ; Kim, Kyung Mann ; Krigel, Robert L. ; Bonomi, Philip D. ; Glick, John H. ; Asbury, Robert F. ; Kirkwood, John M. ; Blum, Ronald H. ; Schiller, Joan H. / A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group study (PZ586). In: Lung Cancer. 1999 ; Vol. 25, No. 3. pp. 199-206.
@article{4bc62306dbbd45edb9d2a7ba55bf0ce6,
title = "A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group study (PZ586)",
abstract = "Interleukin-2 (IL-2) and beta-interferon (β-IFN) are biologic agents with antitumor activity observed in preclinical models. Some studies of patients with advanced non-small cell lung cancer treated with IL-2 report relatively long survival, despite low response rates. Seventy-six evaluable patients with stage IV non-small cell lung cancer were treated in a randomized Phase II study with either IL-2 alone or IL-2 plus β-IFN. Patients received either IL-2 at 6x106 Cetus units/m2 3 days weekly or the combination of IL-2 at 5x106 Cetus units/m2 plus β-IFN at 6x106 units/m2, both given 3 days weekly. Both biologic agents were administered by intravenous bolus injection on an outpatient basis. Objective responses were observed in 3/76 (4{\%}) patients. Grade 4 toxicity occurred in 3/39 patients treated with IL-2 alone, and in 4/37 patients treated with IL-2 plus β-IFN. An additional lethal respiratory toxicity occurred in a patient who received IL-2 plus β-IFN. The median survival of all patients treated on this study was 33 weeks. Despite producing only a 4{\%} objective response rate, IL-2 appears to have a favorable impact on survival comparable to chemotherapy. The role for this immune therapy in the management of non-small cell lung cancer requires further study. Copyright (C) 1999 Elsevier Science Ireland Ltd.",
keywords = "Beta-interferon, Interleukin-2, Non-small cell lung cancer",
author = "Tester, {William J.} and Kim, {Kyung Mann} and Krigel, {Robert L.} and Bonomi, {Philip D.} and Glick, {John H.} and Asbury, {Robert F.} and Kirkwood, {John M.} and Blum, {Ronald H.} and Schiller, {Joan H.}",
year = "1999",
month = "9",
doi = "10.1016/S0169-5002(99)00054-9",
language = "English (US)",
volume = "25",
pages = "199--206",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group study (PZ586)

AU - Tester, William J.

AU - Kim, Kyung Mann

AU - Krigel, Robert L.

AU - Bonomi, Philip D.

AU - Glick, John H.

AU - Asbury, Robert F.

AU - Kirkwood, John M.

AU - Blum, Ronald H.

AU - Schiller, Joan H.

PY - 1999/9

Y1 - 1999/9

N2 - Interleukin-2 (IL-2) and beta-interferon (β-IFN) are biologic agents with antitumor activity observed in preclinical models. Some studies of patients with advanced non-small cell lung cancer treated with IL-2 report relatively long survival, despite low response rates. Seventy-six evaluable patients with stage IV non-small cell lung cancer were treated in a randomized Phase II study with either IL-2 alone or IL-2 plus β-IFN. Patients received either IL-2 at 6x106 Cetus units/m2 3 days weekly or the combination of IL-2 at 5x106 Cetus units/m2 plus β-IFN at 6x106 units/m2, both given 3 days weekly. Both biologic agents were administered by intravenous bolus injection on an outpatient basis. Objective responses were observed in 3/76 (4%) patients. Grade 4 toxicity occurred in 3/39 patients treated with IL-2 alone, and in 4/37 patients treated with IL-2 plus β-IFN. An additional lethal respiratory toxicity occurred in a patient who received IL-2 plus β-IFN. The median survival of all patients treated on this study was 33 weeks. Despite producing only a 4% objective response rate, IL-2 appears to have a favorable impact on survival comparable to chemotherapy. The role for this immune therapy in the management of non-small cell lung cancer requires further study. Copyright (C) 1999 Elsevier Science Ireland Ltd.

AB - Interleukin-2 (IL-2) and beta-interferon (β-IFN) are biologic agents with antitumor activity observed in preclinical models. Some studies of patients with advanced non-small cell lung cancer treated with IL-2 report relatively long survival, despite low response rates. Seventy-six evaluable patients with stage IV non-small cell lung cancer were treated in a randomized Phase II study with either IL-2 alone or IL-2 plus β-IFN. Patients received either IL-2 at 6x106 Cetus units/m2 3 days weekly or the combination of IL-2 at 5x106 Cetus units/m2 plus β-IFN at 6x106 units/m2, both given 3 days weekly. Both biologic agents were administered by intravenous bolus injection on an outpatient basis. Objective responses were observed in 3/76 (4%) patients. Grade 4 toxicity occurred in 3/39 patients treated with IL-2 alone, and in 4/37 patients treated with IL-2 plus β-IFN. An additional lethal respiratory toxicity occurred in a patient who received IL-2 plus β-IFN. The median survival of all patients treated on this study was 33 weeks. Despite producing only a 4% objective response rate, IL-2 appears to have a favorable impact on survival comparable to chemotherapy. The role for this immune therapy in the management of non-small cell lung cancer requires further study. Copyright (C) 1999 Elsevier Science Ireland Ltd.

KW - Beta-interferon

KW - Interleukin-2

KW - Non-small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0032883839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032883839&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(99)00054-9

DO - 10.1016/S0169-5002(99)00054-9

M3 - Article

C2 - 10512131

AN - SCOPUS:0032883839

VL - 25

SP - 199

EP - 206

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -